New alliance seeks to tackle antimicrobial resistance

The British Society for Antimicrobial Chemotherapy (BSAC), the European Bank for Reconstruction and Development (EBRD) and Pfizer have come together to establish an alliance to encourage cooperation between commerce and investment companies with a view to reducing the risk of AMR to both society and the financial sector.

It is in this context that the British Society for Antimicrobial Chemotherapy (BSAC), the European Bank for Reconstruction and Development (EBRD) and Pfizer have come together to establish an alliance to encourage cooperation between commerce and investment companies with a view to reducing the risk of AMR to both society and the financial sector.

The alliance, which is launching to coincide with this year’s annual World Antimicrobial Awareness Week, takes the form of an e-learning advisory network and focuses on negating the threat of AMR through antimicrobial stewardship (AMS) programmes, while also addressing the profound impact Covid-19 has had on global approaches to pandemic prevention and preparedness.

The alliance will be hosted on, and promoted through, BSAC’s Global Antimicrobial Stewardship Partnership Hub (GASPH), which is a learning platform for education and training for the global workforce and civil society.

The tripartite agreement is part of a long-term strategy to bring together civil society and the private sector to boost leadership, skills and awareness in this field and embed AMR and pandemic preparedness in the risk agenda of global investors.